This study thus not only identifies MTE's unrecognized function in anti-T-ALL cells, but also reveals a novel pathway PTEN/PI3K/AKT/mTOR for the effects of MTE on leukemia therapy. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.